Kamada seeks FDA nod for inhaled CF drug trials

10/21/2007 | Globes (Israel)

Israel-based Kamada Ltd. has submitted an application to the FDA for authorization to conduct midstage studies on an inhaled version of Alpha-1 Antitrypsin, the biopharma company's cystic fibrosis treatment. AAT, which is also being developed for the treatment of other illnesses, such as respiratory diseases, could be a cheaper alternative to intravenous drugs for cystic fibrosis, said Kamada CEO David Tsur.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY